Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity

Leukemia

Volumn 29, Issue 2, 2015, Pages 387-395

  Chan, W K ^a   Suwannasaen, D ^a   Throm, R E ^a   Li, Y ^a   Eldridge, P W ^a   Houston, J ^a   Gray, J T ^a   Pui, C H ^a,b   Leung, W ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CD19 ANTIGEN; CD45 ANTIGEN; HISTONE LYSINE METHYLTRANSFERASE; LYMPHOCYTE ANTIGEN RECEPTOR; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN;

ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD45RA NEGATIVE T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL THERAPY; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; GRAFT VERSUS HOST REACTION; HAIR LOSS; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA; LEUKEMIA CELL LINE; MEMORY T LYMPHOCYTE; MIXED LYMPHOCYTE REACTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WEIGHT REDUCTION; ANIMAL; BLOOD; CYTOLOGY; DRUG RESISTANCE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MONONUCLEAR CELL; NEOPLASM; RECURRENT DISEASE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD19; ANTIGENS, CD45; CELL LINE, TUMOR; DRUG RESISTANCE; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; IMMUNOLOGIC MEMORY; LEUKEMIA; LEUKOCYTES, MONONUCLEAR; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASMS; RECEPTORS, ANTIGEN; RECURRENCE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84922578588     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.174     Document Type: Article

References (51)

1. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A et al. Hematopoietic stem cell transplantation: a global perspective. JAMA 2010; 303: 1617-1624.
2. Wayne AS, Giralt S, Kroger N, Bishop MR. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction. Biol Blood Marrow Transplant 2013; 19: 1534-1536.
3. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol 2013; 43: 2797-2809.
4. Cherel M, Choufi B, Trauet J, Cracco P, Dessaint JP, Yakoub-Agha I et al. Naive subset develops the most important alloreactive response among human CD4 T lymphocytes in HLA-identical related setting. Eur J Haematol 2014; 92: 491-496.
5. Chen BJ, Deoliveira D, Cui X, Le NT, Son J, Whitesides JF et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 2007; 109: 3115-3123.
6. Zheng H, Matte-Martone C, Li H, Anderson BE, Venketesan S, Sheng Tan H et al. Effector memory CD4 + T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 2008; 111: 2476-2484.
7. Anderson BE, McNiff J, Yan J, Doyle H, Mamula M, Shlomchik MJ et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003; 112: 101-108.
8. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013; 121: 1165-1174.
9. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010; 16: 1245-1256.
10. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 2013; 10: 267-276.
11. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014; 28: 1596-1605.
12. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257: 107-126.
13. Riddell SR, Jensen MC, June CH. Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond. Biol Blood Marrow Transplant 2013; 19(1 Suppl): S2-S5.
14. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res 2012; 18: 2780-2790.
15. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3: 388-398.
16. Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM et al. Decadelong safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4: 132ra153.
17. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.
18. Riet T, Holzinger A, Dorrie J, Schaft N, Schuler G, Abken H. Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol Biol 2013; 969: 187-201.
19. Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M et al. Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum Gene Ther 2011; 22: 1575-1586.
20. Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 2014; 257: 181-190.
21. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65: 333-347.
22. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol. Hum Gene Ther Methods 2013; 24: 381-391.
23. Field AC, Vink C, Gabriel R, Al-Subki R, Schmidt M, Goulden N et al. Comparison of lentiviral and sleeping beauty mediated alphabeta T cell receptor gene transfer. PLoS One 2013; 8: e68201.
24. Tumaini B, Lee DW, Lin T, Castiello L, Stroncek DF, Mackall C et al. Simplified process for the production of anti-CD19-CAR-engineered T cells. Cytotherapy 2013; 15: 1406-1415.
25. de Boer J, Walf-Vorderwulbecke V, Williams O. In focus: MLL-rearranged leukemia. Leukemia 2013; 27: 1224-1228.
26. Chan WK, Kung Sutherland M, Li Y, Zalevsky J, Schell S, Leung W. Antibodydependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clin Cancer Res 2012; 18: 6296-6305.
27. Throm RE, Ouma AA, Zhou S, Chandrasekaran A, Lockey T, Greene M et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 2009; 113: 5104-5110.
28. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004; 18: 676-684.
29. Aker M, Tubb J, Groth AC, Bukovsky AA, Bell AC, Felsenfeld G et al. Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum Gene Ther 2007; 18: 333-343.
30. Koldej RM, Carney G, Wielgosz MM, Zhou S, Zhan J, Sorrentino BP et al. Comparison of insulators and promoters for expression of the Wiskott-Aldrich syndrome protein using lentiviral vectors. Hum Gene Ther Clin Dev 2013; 24: 77-85.
31. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009; 326: 818-823.
32. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.
33. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-4102.
34. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-4828.
35. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118: 6050-6056.
36. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119: 2709-2720.
37. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra138.
38. Shimasaki N, Fujisaki H, Cho D, Masselli M, Lockey T, Eldridge P et al. A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 2012; 14: 830-840.
39. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106: 376-383.
40. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013; 10: 230-252.
41. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014; 257: 127-144.
42. Greene MR, Lockey T, Mehta PK, Kim YS, Eldridge PW, Gray JT et al. Transduction of human CD34 + repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line. Hum Gene Ther Methods 2012; 23: 297-308.
43. Li S, Yang J, Urban FA, MacGregor JN, Hughes DP, Chang AE et al. Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigenspecific tumor regression. Cancer Gene Ther 2008; 15: 382-392.
44. Kandalaft LE, Powell Jr DJ, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012; 10: 157.
45. Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A et al. Treatment of malignant pleural mesothelioma by fibroblast activation proteinspecific re-directed T cells. J Transl Med 2013; 11: 187.
46. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 2013; 21: 904-912.
47. Song DG, Ye Q, Santoro S, Fang C, Best A, Powell Jr DJ. Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition. Hum Gene Ther 2013; 24: 295-305.
48. Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol 2013; 190: 2455-2463.
49. Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S et al. Infusion of donorderived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 2013; 122: 2965-2973.
50. Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 2013; 122: 4129-4139.
51. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-959.